Peter Godsk Jørgensen1, Magnus T Jensen2, Rasmus Mogelvang2, Bernt Johan von Scholten3, Jan Bech2, Thomas Fritz-Hansen2, Søren Galatius2, Tor Biering-Sørensen2, Henrik U Andersen3, Tina Vilsbøll4, Peter Rossing5, Jan S Jensen6. 1. Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Institute for Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark petergodsk@gmail.com. 2. Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 3. Steno Diabetes Center, Gentofte, Denmark. 4. Institute for Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Center for Diabetes Research, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 5. Institute for Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Steno Diabetes Center, Gentofte, Denmark Faculty of Health, Aarhus University, Aarhus, Denmark. 6. Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark Institute for Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVES: We aimed to determine the prevalence of echocardiographic abnormalities and their relation to clinical characteristics and cardiac symptoms in a large, contemporary cohort of patients with type 2 diabetes. RESULTS: A total of 1030 patients with type 2 diabetes participated. Echocardiographic abnormalities were present in 513 (49.8%) patients, mainly driven by a high prevalence of diastolic dysfunction 178 (19.4%), left ventricular hypertrophy 213 (21.0%) and left atrial enlargement, 200 (19.6%). The prevalence increased markedly with age from 31.1% in the youngest group (<55 years) to 73.9% in the oldest group (>75 years) (p < 0.001) and was equally distributed among the sexes (p = 0.76). In univariate analyses, electrocardiographic abnormalities, age, body mass index, known coronary heart disease, hypertension, albuminuria, diabetes duration and creatinine were associated with abnormal echocardiography along with dyspnoea and characteristic chest pain (p < 0.05 for all). Neither of the cardiac symptoms nor clinical characteristics had sufficient sensitivity and specificity to accurately identify patients with abnormal echocardiography. CONCLUSION: Echocardiographic abnormalities are very common in outpatients with type 2 diabetes, but neither cardiac symptoms nor clinical characteristics are effective to identify patients with echocardiographic abnormalities.
OBJECTIVES: We aimed to determine the prevalence of echocardiographic abnormalities and their relation to clinical characteristics and cardiac symptoms in a large, contemporary cohort of patients with type 2 diabetes. RESULTS: A total of 1030 patients with type 2 diabetes participated. Echocardiographic abnormalities were present in 513 (49.8%) patients, mainly driven by a high prevalence of diastolic dysfunction 178 (19.4%), left ventricular hypertrophy 213 (21.0%) and left atrial enlargement, 200 (19.6%). The prevalence increased markedly with age from 31.1% in the youngest group (<55 years) to 73.9% in the oldest group (>75 years) (p < 0.001) and was equally distributed among the sexes (p = 0.76). In univariate analyses, electrocardiographic abnormalities, age, body mass index, known coronary heart disease, hypertension, albuminuria, diabetes duration and creatinine were associated with abnormal echocardiography along with dyspnoea and characteristic chest pain (p < 0.05 for all). Neither of the cardiac symptoms nor clinical characteristics had sufficient sensitivity and specificity to accurately identify patients with abnormal echocardiography. CONCLUSION:Echocardiographic abnormalities are very common in outpatients with type 2 diabetes, but neither cardiac symptoms nor clinical characteristics are effective to identify patients with echocardiographic abnormalities.
Authors: Maxim Verboven; Lisa Van Ryckeghem; Jamal Belkhouribchia; Paul Dendale; Bert O Eijnde; Dominique Hansen; Virginie Bito Journal: Sports Med Date: 2019-02 Impact factor: 11.136
Authors: Selma Bouthoorn; Aisha Gohar; Gideon Valstar; Hester M den Ruijter; J B Reitsma; Arno W Hoes; Frans H Rutten Journal: Cardiovasc Diabetol Date: 2018-04-18 Impact factor: 9.951
Authors: Regitse H Christensen; Bernt Johan von Scholten; Christian S Hansen; Magnus T Jensen; Tina Vilsbøll; Peter Rossing; Peter G Jørgensen Journal: Cardiovasc Diabetol Date: 2019-08-30 Impact factor: 9.951
Authors: Jesper Jensen; Morten Schou; Caroline Kistorp; Jens Faber; Tine W Hansen; Magnus T Jensen; Henrik U Andersen; Peter Rossing; Tina Vilsbøll; Peter G Jørgensen Journal: Cardiovasc Diabetol Date: 2020-10-16 Impact factor: 9.951
Authors: Peter Godsk Jørgensen; Magnus Thorsten Jensen; Tor Biering-Sørensen; Rasmus Mogelvang; Søren Galatius; Thomas Fritz-Hansen; Peter Rossing; Tina Vilsbøll; Jan Skov Jensen Journal: Cardiovasc Diabetol Date: 2016-09-22 Impact factor: 9.951
Authors: Jelena P Seferovic; Milorad Tesic; Petar M Seferovic; Katarina Lalic; Aleksandra Jotic; Tor Biering-Sørensen; Vojislav Giga; Sanja Stankovic; Natasa Milic; Ljiljana Lukic; Tanja Milicic; Marija Macesic; Jelena Stanarcic Gajovic; Nebojsa M Lalic Journal: Sci Rep Date: 2018-01-17 Impact factor: 4.379
Authors: Peter Blomstrand; Peter Sjöblom; Mats Nilsson; Magnus Wijkman; Martin Engvall; Toste Länne; Fredrik H Nyström; Carl Johan Östgren; Jan Engvall Journal: Cardiovasc Diabetol Date: 2018-08-14 Impact factor: 9.951
Authors: Peter Godsk Jørgensen; Magnus Thorsten Jensen; Tor Biering-Sørensen; Rasmus Mogelvang; Thomas Fritz-Hansen; Tina Vilsbøll; Peter Rossing; Jan Skov Jensen Journal: J Am Heart Assoc Date: 2018-10-02 Impact factor: 5.501